Clearmind Medicine Advances Fight Against Cocaine Addiction with Publication of U.S. Patent Application for Its Non-Hallucinogenic Neuroplastogen MEAI Therapy
Clearmind Medicine (NASDAQ: CMND) announced publication of a U.S. patent application on Oct 31, 2025 expanding intellectual property coverage for its non‑hallucinogenic neuroplastogen MEAI (5‑methoxy‑2‑aminoindane) for treatment of cocaine addiction.
The filing emphasizes MEAI's proposed mechanism—modulation of serotonin and dopamine pathways—and positions the program against a disorder with no FDA‑approved pharmacological treatments. The release cites a global market estimate of $1.36 billion in 2025 growing to $2.03 billion by 2032, and frames the application as strengthening Clearmind's IP portfolio and pipeline strategy for non‑hallucinogenic neuroplastogens.
Clearmind Medicine (NASDAQ: CMND) ha annunciato la pubblicazione di una domanda di brevetto negli Stati Uniti il 31 ottobre 2025, ampliando la copertura di proprietà intellettuale per il suo neuroplastogeno non allucinogeno MEAI (5-metossio-2-aminoindano) per il trattamento della dipendenza da cocaina.
La domanda evidenzia il meccanismo proposto di MEAI—la modulazione delle vie della serotonina e della dopamina—e posiziona il programma contro un disturbo con nessun trattamento farmacologico approvato dalla FDA. Il comunicato cita una stima del mercato globale di 1,36 miliardi di dollari nel 2025, in crescita a 2,03 miliardi di dollari entro il 2032, e presenta la domanda come un rafforzamento del portafoglio IP di Clearmind e della strategia di pipeline per neuroplastogeni non allucinogeni.
Clearmind Medicine (NASDAQ: CMND) anunció la publicación de una solicitud de patente de EE. UU. el 31 de octubre de 2025, expandiendo la cobertura de propiedad intelectual para su neuroplastógeno no alucinógeno MEAI (5-metoxi-2-aminoindano) para el tratamiento de la adicción a la cocaína.
La presentación enfatiza el mecanismo propuesto de MEAI—la modulación de las vías de serotonina y dopamina—y posiciona el programa frente a un trastorno con ningún tratamiento farmacológico aprobado por la FDA. El comunicado cita una estimación del mercado global de 1,36 mil millones de dólares en 2025 que crecería a 2,03 mil millones de dólares para 2032, y enmarca la solicitud como un fortalecimiento de la cartera de PI de Clearmind y de la estrategia de la tubería para neuroplastógenos no alucinógenos.
Clearmind Medicine (NASDAQ: CMND)는 2025년 10월 31일 미국 특허 출원 발표를 통해 비환각 신경플라스토겔 MEAI(5-메톡시-2-아미노인단)의 지적재산권 범위를 확대했습니다. 코카인 중독 치료용.
출원서는 MEAI의 제안된 기전—세로토닌 및 도파민 경로의 조절—을 강조하며, FDA 승인 약물 치료가 없는 장애에 대한 프로그램을 배치합니다. 발표는 2025년 글로벌 시장이 13억 6천만 달러에서 시작해 2032년까지 20억 3천만 달러에 이를 것으로 추정하며, 이 출원을 Clearmind의 지적재산 포트폴리오와 비환각 신경플라스토겔 파이프라인 전략을 강화하는 것으로 설명합니다.
Clearmind Medicine (NASDAQ : CMND) a annoncé la publication d'une demande de brevet américain le 31 octobre 2025, élargissant la couverture de propriété intellectuelle pour son neuroplastogène non hallucinogène MEAI (5-méthoxy-2-aminoindane) pour le traitement de la dépendance à la cocaïne.
Le dossier met l'accent sur le mécanisme proposé par MEAI—la modulation des voies de la sérotonine et de la dopamine—et positionne le programme face à un trouble sans traitements pharmacologiques approuvés par la FDA. Le communiqué cite une estimation du marché mondial de 1,36 milliard de dollars en 2025 qui devrait atteindre 2,03 milliards de dollars d'ici 2032, et présente la demande comme le renforcement du portefeuille IP et de la stratégie de pipeline de Clearmind pour les neuroplastogènes non hallucinogènes.
Clearmind Medicine (NASDAQ: CMND) gab die Veröffentlichung eines US-Patentantrags am 31. Oktober 2025 bekannt, der den IP-Schutz für sein nicht halluzinogenes Neuroplastogen MEAI (5-Methoxy-2-Aminindan) zur Behandlung der Kokainabhängigkeit erweitert.
Die Einreichung betont MEAIs vorgeschlagenen Mechanismus—Modulation von Serotonin- und Dopaminpfaden—und positioniert das Programm gegen eine Störung mit keine von der FDA genehmigten pharmazeutischen Behandlungen. Die Mitteilung nennt eine globale Marktschätzung von 1,36 Milliarden US-Dollar im Jahr 2025, die bis 2032 auf 2,03 Milliarden US-Dollar anwachsen soll, und beschreibt die Anmeldung als Stärkung des IP-Portfolios und der Pipeline-Strategie von Clearmind für nicht halluzinogene Neuroplastogene.
Clearmind Medicine (NASDAQ: CMND) أعلن عن نشر طلب براءة اختراع أمريكي في 31 أكتوبر 2025، موسعاً تغطية الملكية الفكرية لمادة نوروبلاستيغن غير هلوسية MEAI (5-ميثوكسي-2-أمينوإندين) لعلاج إدمان الكوكايين.
يؤكد الطلب الآلية المقترحة لـ MEAI—تعديل مسارات السيروتونين والدوبامين—ويضع البرنامج أمام اضطراب لا توجد له علاجات دوائية معتمدة من FDA. تشير التقديرات إلى أن السوق العالمي يبلغ 1.36 مليار دولار في 2025 ليصل إلى 2.03 مليار دولار بحلول 2032، ويعرض الطلب كتعزيز لمحفظة الملكية الفكرية وخطة خط الأنبوبي لـ Clearmind لمضادات النوروبلاستيغين غير الهلوسينية.
- U.S. patent application published on Oct 31, 2025
- IP coverage expanded for non‑hallucinogenic MEAI
- Global market estimated at $1.36B in 2025
- Patent is an application, not an issued patent
- No clinical efficacy data for MEAI in cocaine addiction disclosed
- Market projection to $2.03B by 2032 is an estimate, not guaranteed
Vancouver, Canada, Oct. 31, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and development of novel neuroplastogen-derived therapeutics to solve major under-treated health problems, today announced the publication of a U.S. patent application expanding coverage of its non-hallucinogenic proprietary compound, 5-methoxy-2-aminoindane (MEAI), for the treatment of cocaine addiction.
The application strengthens Clearmind’s growing intellectual property portfolio and reinforces MEAI’s potential to address a major unmet medical need. Cocaine use disorder affects millions worldwide and currently has no FDA-approved pharmacological treatment. The global market for cocaine addiction treatment is estimated at
MEAI is a novel, non-hallucinogenic neuroplastogen designed to modulate serotonin and dopamine pathways, potentially reducing cravings and supporting long-term recovery. This approach could offer a safer, scalable alternative to existing behavioral interventions.
“Securing protection for MEAI’s potential use in cocaine addiction supports our broader strategy to build a robust pipeline of non-hallucinogenic neuroplastogens,” said Adi Zuloff-Shani, Ph.D., CEO of Clearmind Medicine. “We believe this patent filing represents another key step in positioning Clearmind as a leader in next-generation addiction therapeutics.”
About Clearmind Medicine Inc.
Clearmind is a clinical-stage psychedelic pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods or supplements.
The Company’s intellectual portfolio currently consists of nineteen patent families including 31 granted patents. The Company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio.
Shares of Clearmind are listed for trading on Nasdaq under the symbol "CMND" and the Frankfurt Stock Exchange under the symbol “CWY0.”
For further information visit: https://www.clearmindmedicine.com or contact:
Investor Relations
invest@clearmindmedicine.com
Telephone: (604) 260-1566
US: CMND@crescendo-ir.com
General Inquiries
Info@Clearmindmedicine.com
www.Clearmindmedicine.com
Forward-Looking Statements:
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act and other securities laws. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates” and similar expressions or variations of such words are intended to identify forward-looking statements. For example, the Company is using forward-looking statements when it discusses its growing intellectual property portfolio, MEAI potential to address a major unmet medical need, the growth of the market for the treatment of cocaine use disorder, the Company’s strategy to build a robust pipeline of non-hallucinogenic neuroplastogens and positioning Clearmind as a leader in next-generation addiction therapeutics. Forward-looking statements are not historical facts, and are based upon management’s current expectations, beliefs and projections, many of which, by their nature, are inherently uncertain. Such expectations, beliefs and projections are expressed in good faith. However, there can be no assurance that management’s expectations, beliefs and projections will be achieved, and actual results may differ materially from what is expressed in or indicated by the forward-looking statements. Forward-looking statements are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in the forward-looking statements. For a more detailed description of the risks and uncertainties affecting the Company, reference is made to the Company’s reports filed from time to time with the Securities and Exchange Commission (“SEC”), including, but not limited to, the risks detailed in the Company’s annual report on Form 20-F for the fiscal year ended October 31, 2024 and subsequent filings with the SEC. Forward-looking statements speak only as of the date the statements are made. The Company assumes no obligation to update forward-looking statements to reflect actual results, subsequent events or circumstances, changes in assumptions or changes in other factors affecting forward-looking information except to the extent required by applicable securities laws. If the Company does update one or more forward-looking statements, no inference should be drawn that the Company will make additional updates with respect thereto or with respect to other forward-looking statements. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. Clearmind is not responsible for the contents of third-party websites.
FAQ
What did Clearmind (CMND) announce on Oct 31, 2025 about MEAI?
How does MEAI (CMND) aim to treat cocaine addiction?
What market size did Clearmind cite for cocaine addiction treatment (CMND)?
Does the patent publication mean MEAI is approved for clinical use by the FDA?
Why is the Clearmind MEAI patent application material for investors in CMND?
